StockData

Verrica Pharmaceuticals vs Viridian Therapeutics, Inc.\DE

VRCA and VRDN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How VRCA and VRDN compare

Viridian Therapeutics, Inc.\DE is the larger company, worth 61 times as much as Verrica Pharmaceuticals ($3.4B against $55.0M).

Viridian Therapeutics, Inc.\DE grew revenue faster over the last twelve months (23220% versus 106% for Verrica Pharmaceuticals).

Verrica Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −103% compared with −544% at Viridian Therapeutics, Inc.\DE.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricVRCAVRDN
Size and price
Market cap$55.0M$3.4B
Share price$3.20$29.80
Change, 1 year−17.3%4.6%
Change, 5 years−96.9%62.8%
Beta (5Y)5.05−0.12
Employees76252
StockData Score
Total score44
Valuation score00
Growth score22
Performance score11
Health score11
Dividend score00
Valuation
P/S1.8× (better)47.5×
P/B12.8×5.1× (better)
FCF yield–−9.9%
Fair value–$8.47
Margin of safety–−252%
Growth
Revenue growth (TTM)106%23220% (better)
Revenue growth, 5Y average–132%
Profitability
Operating margin−93.6% (better)−570%
Net margin−103% (better)−544%
FCF margin–−471%
Return on equity–−65.7%
Financial health
Interest coverage−7.6× (better)−26.0×
Current ratio1.4516.95 (better)
Altman Z-score−13.902.61 (better)
Piotroski F-score44
Dividends and buybacks
Buyback yield–−1.7%
Shareholder yield0.00% (better)−1.7%
Ownership
Held by institutions27.1%120%
Held by insiders–21.8%
Insider net buying, 12 months$211K$19.6M (better)
Short interest, % of float–19.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.